EcoDrugPlus

Eph Receptor B4

Ensembl ID : ENSPEMG00000003881
Gene Symbol: EPHB4
1 Cross references
166 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPEMG00000007402
Gene Symbol: F2RL3
3 Cross references
197 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSPEMG00000028282
Gene Symbol: FKBP1A
3 Cross references
232 Possible Orthologues:

Fms-Like Tyrosine Kinase 3

Ensembl ID : ENSPEMG00000012278
Gene Symbol: FLT3
1 Cross references
133 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSPEMG00000020613
Gene Symbol: FXYD2
3 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPEMG00000019599
Gene Symbol: FYN
3 Cross references
261 Possible Orthologues:

Finkel-Biskis-Reilly Murine Sarcoma Virus (Fbr-Musv) Ubiquitously Expressed (Fox Derived)

Ensembl ID : ENSPEMG00000018896
Gene Symbol: FAU
1 Cross references
251 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPEMG00000018553
Gene Symbol: GPR119
3 Cross references
174 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSPEMG00000014168
Gene Symbol: ITK
3 Cross references
207 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSPEMG00000004628
Gene Symbol: JAK1
3 Cross references
236 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSPEMG00000022083
Gene Symbol: JAK2
3 Cross references
265 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSPEMG00000010889
Gene Symbol: JAK3
1 Cross references
103 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).